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ABSTRACT 
Purpose: This is a retrospective study to evaluate the results of our early experience of using doxorubicin eluting 
beads (DEB) to treat patients with early and intermediate hepatocellular carcinoma (HCC). 
Material and methods: A cohort of 19 patients (84.2% male; 15.8% female; mean age 59.2 years ± 11.0; range, 
32-80 years) with documented HCC of size 1.8-10cm (mean, 4.0cm ± 1.8 ) undergoing DEB transarterial 
chembolisation (TACE) was reviewed. All patients had at least one image examination (multiphase computed 
tomography or magnetic resonance imaging) after embolisation. 
Results: A total of 32 procedures were performed. The objective response according to the European Association 
for the Study of the Liver criteria was 57.9% at 1-month, 42.8% at 6-month and 50.0% at 1-year follow up. There were 4 
(21.1%) treatment-related complications (1 liver abscess, 2 pancreatitis and 1 tumour rupture) which resulted in 2 deaths. 
One death occurred 3 weeks after second embolisation, due to ruptured pancreatic pseudocyst, giving a 5.3% 30-day 
mortality rate. Another patient died 2 months after embolisation caused by tumour rupture. Eight patients received 
radiofrequency ablation after embolisation for residual or recurrent tumours. The 1-year survival rate in the DEB TACE 
only group was 80% while the 1- and 2-year survival rate in the group that received radiofrequency after DEB TACE 
was 85.7% and 100% respectively. 
Conclusion: DEB TACE is safe and effective in select group of patients. Survival may be improved when combined 
with other treatment modality. © 2010 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Transarterial chemoembolisation (TACE) involves 
selective delivery of a chemotherapeutic agent such as 
cis-platin, doxorubicin, and mitomycin in an emulsion 
with viscous material such as lipiodol, followed by 
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injection of an embolising agent into the vessel 
supplying the liver tumour. This procedure is 
recommended by the Society of Interventional Radiology 
(SIR) as the first line treatment of inoperable 
hepatocellular carcinoma (HCC) with preserved liver 
function [1]. The advantages of TACE are the ability to 
deliver high concentration of drugs to the tumour and 
reduction of serious systemic side effects such as cardiac 
toxicity, myelosuppression and alopecia compared with 
systemic chemotherapy. TACE functions by de-
arterialisation of tumour by the embolic agents and 
selective delivery of chemotherapeutic agents to the 
tumour. Recent randomised trials and studies have 
shown statistical survival benefits and improved 
therapeutic efficacy of TACE in unresectable HCC over 
supportive care or systemic chemotherapy [2, 3, 4]  
Recently, embolic microspheres that have the ability 
to sequester doxorubicin hydrochloride from the solution 
and release it in a controlled and sustainable fashion 
were introduced for intra-arterial injection. The 
embolisation particles are made from a unique drug-
eluting technology i.e., doxorubicin-eluting beads (DEB), 
based on a hydrogel that has been modified with 
sulphonate group [5]. They are available in diameters 
ranging from 40 to 1200 µm designed to allow gradual 
release of chemotherapy over time, to prolong the 
contact time between cancer cells and to avoid damage 
of the hepatic microcirculation [6]. Selective delivery of 
the loaded beads into the feeding arteries leads to vessel 
lumen occlusion and ischaemia, while doxorubicin is 
gradually released locally, leading to tumour necrosis [5, 
7, 8]. Several studies have shown that following DEB 
TACE, systemic levels of doxorubicin are reduced 
significantly when compared with conventional TACE [8, 
9, 10]. DEB has been shown to elute doxorubicin over a 
sustained period of time resulting in greater tumour 
response [7].  
In this paper, the authors present the results of their 
early experience treating 19 confirmed HCC patients 
using DEB. The study population includes patients with 
early and intermediate HCC (stage A and B). They also 
calculated the survival rate of patients who received 
radiofrequency ablation after DEB TACE.  
MATERIAL AND METHODS 
Patients 
This study is a retrospective cohort study based on 
the analysis of 19 patients (16 male and 3 female, mean 
age 59.2 years ± 11.0) with HCC, treated with 
transarterial embolisation of doxorubicin-eluting DC 
beads (Biocompatibles UK, Surrey, UK) from February 
2007 to October 2008 in a single centre. Following 
embolisation, all patients had at least one follow-up 
imaging with either multiphase CT or MRI. Diagnosis of 
HCC was either confirmed by biopsy or based on 
radiological findings and alpha-feto protein level 
according to the Barcelona criteria [11]. The inclusion 
criteria for treatment with doxorubicin loaded beads were 
as follows: patients with HCC who were not suitable for 
resection, liver transplantation or percutaneous ablation; 
patients who developed recurrence following resection, 
percutaneous ablation or conventional TACE and 
patients who have declined surgery or radiofrequency 
ablation. Liver function criteria for enrolment included 
bilirubin <51 µmol/L and liver enzymes (aspartate 
aminotransferase and alanine aminotransferase) 
< 270 IU/L.  
The exclusion criteria for treatment with 
doxorubicin (DC) loaded beads were patients with: 
extrahepatic metastasis, portal vein invasion, 
portosystemic shunts, encephalopathy, gastrointestinal 
bleeding, contraindication for hepatic embolisation 
(impaired clotting tests, renal insufficiency/failure, sepsis 
and bleeding coagulopathy) and tumour burden >50% of 
the liver volume. 
Embolisation technique and surveillance imaging 
All procedures were performed in the interventional 
radiology suite by interventional radiologists after 
informed consent for the procedure was obtained from 
the patients; approval of an ethics committee was not 
required. Prior to embolisation, angiography of the 
coeliac and hepatic artery was performed to determine 
the feeding arteries of the tumour, identify variation in 
the liver arterial supply and exclude portal venous 
shunting. Loading of the beads was done in vitro an hour 
before the beginning of catheterization. The loaded beads 
were then aspirated from the vial into a syringe filled 
with nonionic contrast medium. Three different sizes of 
DC beads were used, 100-300 μm, 300-500 μm and 
500-700 μm. The diameter of the beads chosen depended 
on the calibre of the feeder, size of tumour and 
vascularity of the tumour. For small tumours measuring 
less than 3 cm, DC beads of 100-300 μm were used 
while DC beads of 300-500 μm and 500-700 μm were 
used for larger tumours. Once the feeding artery was 
identified and catheter was in placement, the loaded 
beads were infused slowly under fluoroscopic guidance. 
The injection of the loaded beads was performed as 
selective as possible using either a 4F diagnostic catheter 
(hepatic catheter or Yashiro) or 2.7F microcatheter 
(Progreat; Terumo). For diffuse or multifocal tumours, 
lobar or segmental embolisation was performed. The 
beads were injected distal to the origin of the 
gastroduodenal, right gastric and cystic artery. Pre-
treatment coil embolisation of non target arteries was not 
performed in any of the patients. The embolisation 
endpoint was sluggish flow of the tumour feeder vessels. 
Intravenous analgesia and antiemetic were administered 
before and during the procedure.  
Follow up imaging was performed 4 weeks after 
embolisation and every 3 months after that. Repeat 
embolisation was scheduled “on demand” basis, 2 to 
4  weeks after follow up imaging if there was residual 
viable tumour deemed unsuitable for radiofrequency 
ablation or surgery.  
All CT scan studies were performed with a 16-slice 
multidetector CT (Light speed, General Electric Medical 
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Systems, USA and Siemen Somatom Sensation 16, 
Munich, Germany). CT examination was performed 
using a 5-phase protocol including a non-enhanced 
acquisition. Early arterial phase (delay 20 s), late arterial 
phase (delay 30 s), portal venous phase (delay 60 s) and 
delayed venous phase (delay 80 s) were obtained using 
120 mL of contrast (Iopromide 300 mg I/L, Schering, 
Germany) at a rate of 4 mL/s. The images were acquired 
with slice thickness 1.25 mm, collimation 2.5 mm and 
table speed 7.5 mm per gantry rotation. In a few select 
patients, gadoxetic acid enhanced MRI using General 
Electric 1.5 Tesla Signa (GE Medical System, 
Milwaukee, Wisconsin) was performed. 
Outcome measures 
Tumour response to procedure was evaluated 
according to the amount of tumour necrosis detected on 
CT or MRI follow-up imaging as recommended by 
European Association for the Study of the Liver Disease 
(EASL) [12]. The EASL acknowledges “viable areas” as 
those that “present enhancement” and “necrotic” as those 
that “do not present enhancement”. In the EASL criteria, 
complete response (CR) is defined as complete 
disappearance of all known disease and no new lesions 
are seen; partial response (PR) when a 50% reduction in 
all tumoural area of all measurable lesions is present; 
stable disease (SD) in all other cases and progressive 
disease (PD) when there is 25% increase in size of one or 
more measurable lesions or if new lesions appear. 
Objective response (OR) included both a complete and 
partial response. Patients who underwent other treatment 
modalities (radiofrequency ablation, conventional TACE, 
surgical resection) following DC beads embolisation 
were analysed separately. The authors considered a 
complication that occurred within 4 weeks of the 
embolisation as procedure-related complication.  
Statistical analysis 
Statistical analysis was performed using SPSS 
version 17. Values for all continuous variables are 
quoted as mean, standard deviation, minimum and 
maximum throughout. The paired t-test was used to 
demonstrate changes in biochemistry over time.  
RESULTS  
Patients 
Table 1 tabulates baseline characteristics, response 
and survival of patients analysed in this series. Of the 
19  patients that underwent the procedure, 12 (63.2%) 
patients presented with Child-Pugh score A and 7 (36.8%) 
with Child-Pugh score B. Fifteen (78.9%) patients had 
liver cirrhosis out of which 2 had hepatitis C virus 
(HCV)-related cirrhosis, 8 had hepatitis B virus (HBV)-
related cirrhosis, 1 had alcohol-induced cirrhosis and 4 
had cryptogenic cirrhosis. The patients were also staged 
according to the Barcelona Clinic Liver Cancer (BCLC) 
Staging system with 4 (21.1%) of 19 patients presenting 
with early stage (A) and the rest (78.9%) presenting with 
intermediate stage (B) [12]. 
Seven of the 19 patients presented with single 
tumour while the rest had multicentric disease. Of the 
12  patients that presented with multicentric disease, 
9 patients had less than 5 lesions, 2 had 5 to 10 lesions 
and 1 patient had 12 lesions. The total number of lesions 
was 62 and the mean tumour diameter was 4.0 ± 1.8 cm. 
Eleven (57.9%) patients were found to have unilobar 
disease with right lobe involvement seen in 10 of them. 
The rest (42.1%) of the patients presented with bilobar 
disease.  
Procedural 
A total of 30 embolisations were performed. All 
procedures were technically successful with no 
intraprocedural complication encountered. Ten patients 
(52.6%) received single embolisation, 7 patients 
completed 2 embolisations and 2 patients completed 
3 sessions. A total of 32 vials of DC beads were used 
(mean, 1.7 vials per patient) with a maximum dose of 
150 mg (range: 50 mg to 150 mg) per session. 
Radiofrequency ablation (RFA) was performed on 
8  patients following embolisation for residual or 
recurrent tumour. Two patients received 2 RFA sessions 
after embolisation. A total of 10 RFA sessions were 
performed.  
Biochemical 
Periprocedural laboratory test showed no 
statistically significant change in the level of bilirubin 
and gamma-glutamyl transferase after the procedure 
compared to the baseline. However, there was significant 
rise of alanine aminotransferase (p = 0.03) and aspartate 
aminotransferase (p = 0.002) 1 to 3 days after 
embolisation which returned to baseline 3 to 5 weeks 
after the procedure.  
Tumour response 
Table 2 reports the tumour response according to the 
EASL assessment criteria of patients treated with only 
DEB TACE at 1-month, 6-month and 12-month follow-
up. Figure 1 and 2 illustrate a case of complete response 
and partial response, respectively.  
At 1-month follow-up, complete response was seen 
in 4 of the 19 patients (21.1%) and partial response was 
documented in 6 patients (31.5%). Five patients (26.3%) 
showed stable disease and 4 patients (21.1%) showed 
progressive disease. Objective response was seen in 
52.6% of patients. There was no mortality recorded 
within 30 days of the embolisation. 
At 6-month follow up, 1 patient was lost to follow 
up (patient 12) and 4 patients underwent RFA (patient 3, 
6, 10, 16). Hence, 14 patients were available for the 
6-month follow up. Six patients had completed 
2 sessions of embolisation, with a treatment-related death 
recorded in one of the patients (patient 2). The death, 
which occurred 3 weeks after the second embolisation, 
was caused by cardio-circulatory collapse due to a 
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Table 1  Baseline characteristics, response and survival of patients. 
Patient Age Sex  BCLC 
stage 
Aetiology of 
HCC 
Number of 
lesions 
HCC size 
(mm) 
Number of  
DEB-TACE 
received 
Other treatments 
after DEB-TACE 
Response at 
1/6/12 months (m)  Survival (months) 
1  65  Male  B  Cryp Cirr  2  50, 100  2    PD / PR / PD  12 m, then lost to f/up 
2  54  Male  B  Hep B  1  95  2    SD / - / -  3 m, died due to 
pseudocyst rupture 
3  64  Male  A  Hep B  1  26  2  RFA  PR / SD / -  8 m, on f/up 
4  61  Male  B  Hep B  7  20 - 43  3    SD / SD / PR  18m, died due to 
progressive liver disease 
5  80  Female  A  Hep C  1  18  2    PR / PR / CR  12m, on f/up 
6  50  Male  A  Hep C  1  35  1  RFA  PR / CR / CR  15m, on f/up 
7  67  Male  B  Hep C  1  70  2    SD / SD / -  10m, then lost to f/up 
8  73  Female  B  Cryp Cirr  1  63  1    PR / CR / CR  14m, on f/up 
9  61  Male  B  Hep B  4  20 - 35  1    CR / CR / CR  18m, on f/up 
10  60  Male  B  Cryp Cirr  12  25 - 30  1  RFA  PD / PD / -  11m, died due to 
disease progression 
11  66  Male  B  Alc Cirr  8  25 - 35  1    PR / - / -  2m, died due to tumour 
rupture 
12  58  Male  B  Cryp cirr  2  16, 120  1    PD / - / -  1m, then lost to f/up 
13  32  Male  B  Hep B  4  24 - 42  1  Surgery  CR / PD / PD  14 m, on follow up 
14  38  Male  A  Hep B  1  37  1    CR / CR / CR  18m, on f/up 
15  52  Male  B  Hep B  4  42 - 63  3  RFA  PR / PD / PD  19.5m, on f/up 
16  64  Male  B  Hep B  4  31 - 44  1  RFA  PR / PR / PR  19m, on f/up 
17  59  Male  B  Hep B  2  28, 50  1  RFA  PD / PR / SD  18m, on f/up 
18  61  Male  B  Hep B  4  32 - 50  2    SD / PD / PD  16m, on f/up 
19  59  Female  B  Hep B  2  60, 60  2  RFA  CR / PD / SD  27.5m, then lost to f/up 
Cryp Cirr: Cryptogenic cirrhosis; Alc Cirr: Alcohol induced cirrhosis 
CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease 
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(c) 
Figure 1  Multiphase CT in arterial phase showing a focal enhancing lesion in segment 6 (A). Angiogram before 
embolisation shows tumour (arrows) supplied by the branch of right hepatic artery (B). Multiphase CT 
in arterial phase 1 month after embolisation reveals complete disappearance of tumour, in keeping with 
complete response (C). 
 
 
   
(a) (b) 
Figure 2  Multiphase CT in arterial phase showing a heterogenously enhancing lesion in the right lobe of liver 
(A). 1-month follow up CT in arterial phase shows tumour necrosis of most of the tumour with a small 
residual nodule at the periphery, in keeping with partial response (B). 
O Nawawi et al. Biomed Imaging Interv J 2010; 6(1):e7 5
This page number is not
for citation purposes 
ruptured pancreatic pseudocyst. Another patient died 
2 months after one embolisation believed to be caused by 
tumour rupture (patient 11). The ruptured tumour 
showed partial response at the 1-month follow up 
CT  scan. Objective response was documented in 
6 (42.8%) of 14 patients with complete response seen in 
3 patients and partial response recorded in 3 patients. 
One of the patients (patient 15) classified as having 
progressive disease by EASL criteria showed partial 
response of the initial target lesion but developed new 
lesion in the non targeted part of the liver.  
At 12-month follow-up, another patient (patient 7) 
defaulted follow up and an additional 3 patients (patient 
15, 18 and 19) underwent RFA. Sustained complete 
response was seen in 3 (30%) of 10 patients and 
sustained partial response seen in 2 (20%) patients. 
Survival at 12 months was 80%.  
One patient underwent liver resection of new 
tumour lesion at 13 months (patient 13). One patient 
(patient 4) died at 18 months due to disease progression. 
No patient was available for the 24-month follow up. 
The mean duration of follow-up for patients who 
received DEB TACE only was 12.9 months ± 6.1 (range, 
1 - 18 months). 
Seven patients (36.8%) in this series received RFA 
after the first embolisation while 1 patient (5.2%) was 
ablated after the second embolisation, for residual or 
recurrent tumour. For these patients, the 1- and 2-year 
survival rate following the first embolisation was 85.7% 
(6 of 7) and 100% (1 of 1), respectively. One patient 
(patient 12) who underwent 2 sessions of RFA post 
embolisation succumbed to the disease 11 months from 
the time of embolisation. There was no treatment-related 
complication in this group of patients. The mean duration 
of follow up was 17 months ± 5.9 (range, 8 to 
27.5 months). 
Side effects and complications 
Pancreatitis resulting in treatment-related mortality 
was observed in one patient (patient 2) with intermediate 
HCC, after the second embolisation. The pancreatitis, 
which occurred 5 days after the embolisation and 
managed conservatively, was complicated by 
pseudocysts. Unexpectedly, one of the pseudocysts 
ruptured causing the patient to go into cardio-circulatory 
collapse. The death was the only 30-day mortality in this 
series. Another patient (patient 14) was retrospectively 
diagnosed to have pancreatitis after the 6-month follow 
up MRI revealed a 5 cm pancreatic pseudocyst. On 
further questioning, the patient gave a history of having 
intermittent ‘indigestion-like’ symptoms 3 months after 
the embolisation, which gradually worsened in the 
subsequent months. The pancreatic pseudocyst was then 
percutaneously aspirated under ultrasound guidance and 
the patient was completely asymptomatic following the 
aspiration.  
One death (patient 11) occurred 8 weeks after 
embolisation, believed to be caused by rupture of the 
largest tumour, giving a treatment-related death of 10.5%. 
The tumour that ruptured measured 6 cm in diameter and 
was radioablated 5 times before the DEB TACE 
procedure.  
Liver abscess was recorded in 1 patient (patient 13), 
2 months after the second embolisation. The collection 
was successfully drained percutaneously but the patient 
underwent a resection 4 months later after a follow up 
CT revealed a recurrence at the margin of the resolving 
liver abscess. Overall, the total number of complications 
was 4 out of 19 patients (21.1%). 
Post embolisation syndrome defined as fever, 
nausea, vomiting or abdominal pain was observed in all 
patients following the first procedure and 4 of 9 patients 
following the second session. The maximum hospital 
stay for post embolisation syndrome was 7 days. The 
median hospital stay was 1 day. There was no 
doxorubicin systemic toxicity (alopecia, marrow 
suppression or cardiac failure) documented in these 
patients.  
DISCUSSION 
HCC is the fifth most common cancer globally with 
over 600,000 new cases diagnosed worldwide each year 
[13]. The incidence in developing countries is two to 
Table 2  Tumour response based on EASL criteria at 1-, 6- and 12-month follow up. 
Outcome 1-month  follow  up 
N (%) 
6-month follow up 
N (%)  
12-month follow up 
N (%)  
CR   4 (21.1)   3 (21.4)   3 (30.0) 
PR   7 (36.8)  3 (21.4)  2 (20.0) 
SD   4 (21.0)  2 (14.3)  0 ( 0.0) 
PD   4 (21.1)  4 (28.6)  3 (30.0) 
OR  11 (57.9)  6 (42.8)  5 (50.0) 
Death   0 ( 0.0)  2 (14.3)  2 (20.0) 
CR: Complete Response; PR: Partial Response; SD: Stable Disease;  
PD: Progressive disease; OR: Objective response 
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three times higher than in developed countries [14]. In 
Malaysia, HCC is among the ten most common cancers 
in the male population with a distinct predilection for 
Chinese [15, 16]. It is the leading cause of death in 
cirrhotic patients. Surgery, as a curative option carries 
significant perioperative mortality and morbidity in 
patients with cirrhosis and is indicated only in patients 
with single HCC without portal hypertension and 
preserved liver function [17, 18]. In patients with HCC 
that is not suitable for curative treatment, TACE 
represents the first-line approach that can improve 1- and 
2-year survival [3, 11, 19]. The choices of 
chemotherapeutic agent and embolisation material may 
vary from centre to centre, however, the common 
denominator of this procedure is the intra-arterial 
injection of emulsified chemotherapeutic agent with 
viscous agent. The aim of the procedure is to deliver 
chemotherapeutic agents to the tumour selectively, and at 
the same time to induce ischaemic necrosis of the tumour. 
Drug-eluting beads are new embolic agents for 
TACE that can be loaded with chemotherapeutic agent 
and designed to allow gradual release of 
chemotherapeutic agent locally and reduce the systemic 
toxicity of chemotherapeutic agent. In vivo study has 
documented that animals treated with DEB showed 
significantly lower plasma concentration of doxorubicin 
compared with control animals treated with doxorubicin 
intraarterially. This suggests higher tumour retention of 
doxorubicin in animals treated with DEB [19]. The high 
affinity for doxorubicin and the slow-release mechanism 
are unique properties of DEB that were not observed 
with other commercially available embolisation agents 
[5]. Varela et al conducted the first human trial on 
doxorubicin loaded DC Beads, on Child-Pugh A 
cirrhotic patients with large or multifocal HCC. They 
confirmed that peak plasma doxorubicin level was lower 
with DEB compared with that of doxorubicin-lipiodol 
emulsion [10]. 
As with previous DEB TACE studies, there was no 
systemic toxicity from doxorubicin observed in this 
study [9, 10, 20, 21]. The total incidence of complication 
observed in this series was 12.5% per procedure or 
21.1% per patient, comprising of 2 pancreatitis, 1 liver 
abscess and 1 tumour rupture. Two of the complications 
resulted in 10.5% of treatment-related death. The 
incidence of serious treatment-related complication and 
treatment-related death following conventional TACE 
had been reported to be 27.5% and 9.4%, respectively [4, 
22]. Earlier investigators of DEB TACE had documented 
major complication rate of 7.4% and 42.9% and 
treatment-related death of 14.3% in their series [8, 23]. 
Overall, the complications encountered in this cohort are 
known complications of TACE that are reported to range 
from 0% to 50% [24].  
Fatal outcome due to tumour rupture following 
TACE has been documented, usually in patients with 
large subcapsular tumours, as was the case in the authors' 
patient [25, 26]. Increased intratumoural pressure as a 
result of tumour necrosis or vascular injury secondary to 
embolisation has been thought to be the mechanism of 
tumour rupture following TACE [25].  
Pancreatitis is an uncommon complication following 
embolisation, but has a significant morbidity and 
mortality potential if associated with local or systemic 
complications [27]. Clinically evident acute pancreatitis 
after embolisation occurs at an incidence between 1.7% 
and 4% but typical laboratory findings consistent with 
pancreatitis is shown in 40% of patients [28, 29]. The 
diagnosis of acute pancreatitis following embolisation 
can be missed as it can clinically mimic postembolisation 
syndrome, as was the case in the authors' patient. Hence, 
careful monitoring of serum pancreatic enzymes should 
be employed in cases of abdominal pain following 
TACE [27]. The proposed mechanism of pancreatitis 
following TACE is inadvertent embolisation through 
collateral vessels or regurgitation of embolic particles or 
chemotherapeutic agents to the non targeted arteries [30, 
31]. Similar causative factors are used to explain a 
variety of other complications related to hepatic intra-
arterial treatment especially to the gastroduodenal region. 
Acute cholecystitis attributed to inadvertent embolisation 
of the cystic artery was reported following DEB TACE 
[20]. In order to avoid serious adverse effects or damage 
to the gastroduodenal territory due to misdistribution of 
embolic or chemotherapeutic agents, embolisation of the 
gastroduodenal artery can be performed prior to 
embolisation [32, 33]. Prophylactic embolisation of 
nontarget arteries is a well-established approach to 
protection of non target organs in 
90Y SIR-Spheres 
embolisation [34]. In view of the high chemoembolic 
mechanism of action of DEB and documented incidence 
of fatal pancreatitis in this series, similar preventive 
measures may be taken to avoid repeat incidence of fatal 
complications of non target organs, especially in cases 
where superselective injection are not possible.  
Liver abscess is a well known DEB TACE related 
complication which had contributed to treatment-related 
mortality [2, 10, 23]. The 5.3% incidence of liver abscess 
in this series is comparable to previous studies which 
ranged between 1.6% to 14.2% [10, 20, 23]. The most 
important predisposing factor for this complication is the 
presence of biliary abnormality prone to ascending 
biliary infection such as bilio-enteric anastomosis, bilio-
enteric fistula, endoscopic papillotomy and percutaneous 
biliary drainage [35]. These risk factors were was not 
present in the authors' patient (patient 13). Abscess 
formation after conventional TACE of 1.2% to 2% seems 
lower than after DEB TACE [1, 35, 36]. The reason for 
this observation could be due to the fact that unlike 
gelfoam particles used in conventional TACE, the beads 
used in DEB TACE are non-reabsorbable and can cause 
permanent ischemic damage to the liver [23].  
The authors adopted the EASL criteria as their 
choice of monitoring treatment response as they take into 
account the development of necrosis, which better 
describe the effect of treatment. The parameter of 
necrosis is not taken into account in the Response 
Evaluation Criteria in Solid Tumours (RECIST), which 
measures the size of treated lesion. It is acknowledged 
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that it is common for liver tumours to liquefy without 
significant change in total lesion diameter within short 
follow-up periods and that extensive tumour necrosis 
may not be paralleled by a reduction in the diameter of 
the lesion [11, 37].  
The authors observed an objective response that 
ranged from 42.8% to 57.9% across 1 year (Table 2). 
Sustained objective response was recorded in 5 (50%) at 
12-month follow up. These values are slightly lower than 
previous DEB TACE studies but higher than 
conventional TACE clinical trials of 16-35% [2, 4, 10, 
20, 22, 38, 39, 40]. Malagari et al in their DEB TACE 
trials on unresectable HCC reported objective response 
rate of 59.6% to 80.7% [20]. However, unlike the 
authors' series where patients with multicentric disease 
make up 63.2% of the study population, only patients 
with solitary tumour were included in their study [20]. 
One patient with complete response of the initial target 
lesion developed new lesions at the non targeted part of 
the liver at 6-month follow up and, hence, classified as 
having progressive disease (patient 19). These new 
lesions were either microscopic foci undetected by 
imaging at the time of recruitment or new multicentric 
tumours. Such lesions were probably not covered during 
treatment due to the selective delivery of DEB [38]. 
The 1-year survival rate of 80% in this study is 
similar if not higher than that of conventional TACE. In 
TACE studies where lobar embolisation was performed 
in 49% of the cases, the 1-, 2-, and 3-year survival rates 
were reported at 57, 31 and 26%, respectively [2]. In 
another paper where segmental TACE was applied in 
relatively small cancers which are potentially suitable for 
RFA, survival was 80%, 43%, and 23% at 1, 3 and 
5  years, respectively [41]. Comparatively, the survival 
rate of patients who presented with single small HCC 
(< 4 cm) in the authors' series was 100% at 1-year. These 
were patients who had refused surgery, or who presented 
with new lesion after a successful RFA. Not surprising 
this small cohort of patients also achieved 100% 
objective response across 1 year.  
A total of 42% of patients in the authors' series 
underwent RFA after DEB TACE. In view of the 
considerably high rate of patients in this group the 
authors have also included the survival analysis of this 
cohort. The 1-year survival rate of 85.7% (following the 
first embolisation) was slightly higher than that of the 
DEB TACE only group. At the time of writing, only 
1  death was recorded at 11 months after the first 
embolisation. The longest surviving patient in this study 
belonged in this group. The patient survived 27.5 months 
after embolisation and was in partial response at 
24-month follow up. Improved survival time had been 
reported in patients with early HCC treated with 
resection or TACE followed by RFA as compared to 
patients receiving TACE alone [42]. Early literature on 
patients with unresectable HCC treated with RFA after 
TACE reported promising mid-term clinical success with 
projected 1- and 2-year survival rate of 89.7% and 67.1%, 
respectively [43]. However, the overall usefulness of this 
combined therapy has yet to be established by large 
series and risk-benefit analysis. 
In summary, the review of the authors' early 
experience shows that DEB TACE is well tolerated and 
effective in treating patients with early and intermediate 
HCC. When combined with other treatment modality, the 
survival time can be prolonged.  
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